gallium (68Ga) gozetotide (25μg)

Phase 3

gallium (68Ga) gozetotide (25μg) is one of 3 therapeutic programs targeting Oligometastatic Prostate Cancer (OMPC). It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Oligometastatic Prostate Cancer (OMPC)Recruiting

Oligometastatic Prostate Cancer (OMPC)Phase 3

Recruiting

Competition

Competitive Landscape

2 competitors in Oligometastatic Prostate Cancer (OMPC)

#DrugCompanyPhaseTrials

AAA617

Novartis

Phase 3

1 2

Piflufolastat

Novartis

Phase 3

1 3

gallium (68Ga) gozetotide (25μg)

Novartis

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

Phase 3Recruiting

Oligometastatic Prostate Cancer (OMPC)

NCT05939414

Clinical

Trials by Indication[1]

Oligometastatic Prostate Cancer (OMPC)1 trial

An International, Prospective, Open-label, Multi-center, Randomized Phase III Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) Versus Observation to Delay Castration or Disease Recurrence in Adult Male Patients With Prostate-specific Membrane Antigen (PSMA) Positive Oligometastatic Prostate Cancer (OMPC)

Recruiting· Novartis logo

Novartis·Phase 3·NCT05939414·450 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for gallium (68Ga) gozetotide (25μg). U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for gallium (68Ga) gozetotide (25μg). EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Novartis

gallium (68Ga) gozetotide (25μg)

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2031

Trials by Indication[1]

Oligometastatic Prostate Cancer (OMPC)1 trial

References

Drug Info

Quick Facts

Related News